PFE
Pfizer Inc
NYSE: PFE · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$29.95
+1.68% today
Updated 2026-10-29
Market cap
$168.60B
P/E ratio
38.92
P/S ratio
2.65x
EPS (TTM)
$0.76
Dividend yield
5.84%
52W range
$23 – $30
Volume
31.9M
WallStSmart proprietary scores
49
out of 100
Grade: C
Sell
Investment rating
2.7
Growth
F5.5
Quality
C+6.0
Profitability
B3.3
Valuation
D4/9
Piotroski F-Score
Moderate
1.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$28.57
-4.59%
12-Month target
$26.90
-10.17%
Intrinsic (DCF)
$29.99
Margin of safety
-0.13%
2 Strong Buy8 Buy16 Hold1 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $302.00M — positive
Risks
- Altman Z 1.70 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $101.17B | $59.55B | $63.63B | $62.58B | $63.70B | $61.8B |
| Net income | $31.37B | $2.12B | $8.03B | $7.77B | $-248.00M | — |
| EPS | — | — | — | — | $0.76 | $2.99 |
| Free cash flow | $26.03B | $4.79B | $9.84B | $9.08B | $302.00M | — |
| Profit margin | 31.01% | 3.56% | 12.62% | 12.42% | 6.80% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-10-15 | BOURLA, ALBERT | Buy | 20 | $29.44 |
| 2026-10-13 | BOURLA, ALBERT | Buy | 71 | $28.37 |
| 2026-09-30 | BOURLA, ALBERT | Buy | 21 | $28.52 |
Peer comparison
Smart narrative
Pfizer Inc trades at $29.95. representing a P/E of 38.92x trailing earnings. Our Smart Value Score of 49/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.70, it sits in the distress. TTM revenue stands at $63.70B. with profit margins at 6.80%. Our DCF model estimates intrinsic value at $29.99.
Frequently asked questions
What is Pfizer Inc's stock price?
Pfizer Inc (PFE) trades at $29.95, on a P/E of 38.9x and a P/S of 2.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Pfizer Inc overvalued?
Pfizer Inc carries a Smart Value Score of 49/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $29.99 against the $29.95 price, so on cash flow terms the market is paying a premium for Pfizer Inc's growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Pfizer Inc (PFE)?
The 12-month analyst consensus target is $28.57, about 4.6% below the current $29.95. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of PFE by 2030?
Our research-backed model puts the 2030 base case at $135.94, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Pfizer Inc (PFE)?
Our DCF model estimates intrinsic value at $29.99, a -0.1% margin of safety versus today's $29.95. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Pfizer Inc's revenue?
Pfizer Inc's trailing twelve-month revenue is $63.70B, and our model projects it reaching about $65.50B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Pfizer Inc's Altman Z-Score is 1.70, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.65x
ROE5.09%
Beta0.28
50D MA$27.97
200D MA$26.56
Shares out5.70B
Float5.69B
Short ratio—
Avg volume31.9M
Performance
1 week-2.04%
1 month+3.76%
3 months+19.63%
YTD+21.68%
1 year+26.94%
3 years—
5 years—